Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over
Clinical studies have shown impressive results: Semaglutide Average weight loss: 1215% of body weight Tirzepatide Average weight loss: 1822% of body weight Many patients lose 1025 kg over 1218 months when combined with healthy eating and physical activity
Their primary mechanisms of action include: Enhancing glucose-dependent insulin secretion from pancreatic beta cells Suppressing glucagon release , thereby reducing hepatic glucose production Slowing gastric emptying , which moderates post-meal glucose spikes Reducing appetite through central nervous system effects, particularly in hypothalamic regions Promoting satiety , leading to reduced caloric intake These medications have demonstrated significant benefits in glycaemic control, weight reduction, and cardiovascular risk reduction in clinical trials
However, depending on where you are, certain treatments not be available
Semaglutides anti-inflammatory properties can help mitigate these risks, promoting heart health and longevity
Some patients adjust to this within a few weeks